IO Biotech CEO a panelist at Cancer Progress Conference

Apr 2, 2014

CEO of IO Biotech, Mai-Britt Zocca, will be sitting at the Immuno-Oncology I: Attacking Cancer Antigens – Exploiting Off-the-Shelf And Personalized Vaccines and Triggering of Immunogenic Cell Death panel for the 27th Annual Cancer Progress Conference, in New York City on March 8-9, 2016.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial